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Abstract
Background: The UK Genotyping and Phenotyping of Platelets study has recruited 
and analyzed 129 patients with suspected heritable bleeding. Previously, 55 individu-
als had a definitive genetic diagnosis based on whole exome sequencing (WES) and 
platelet morphological and functional testing. A significant challenge in this field is 
defining filtering criteria to identify the most likely candidate mutations for diagnosis 
and further study.
Objective: Identify candidate gene mutations for the remaining 74 patients with 
platelet-based bleeding with unknown genetic cause, forming the basis of future re-
recruitment and further functional testing and assessment.
Methods: Using python-based data frame indexing, we first identify and filter all 
novel and rare variants using a panel of 116 genes known to cause bleeding across 
the full cohort of WES data. This identified new variants not previously reported 
in this cohort. We then index the remaining patients, with rare or novel variants in 
known bleeding genes against a murine RNA sequencing dataset that models pro-
platelet-forming megakaryocytes.
Results: Filtering against known genes identified candidate variants in 59 individu-
als, including novel variants in several known genes. In the remaining cohort of “un-
known” patients, indexing against differentially expressed genes revealed candidate 
gene variants in several novel unreported genes, focusing on 14 patients with a se-
vere clinical presentation.
Conclusions: We identified candidate mutations in a cohort of patients with no previ-
ous genetic diagnosis. This work involves innovative coupling of RNA sequencing and 
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1  | INTRODUC TION
The UK Genotyping and Phenotyping of Platelets (GAPP)1 study 
previously reported a cohort of 55 patients with whole exome se-
quencing (WES) recruited from hemophilia centers nationwide with 
a significant clinical history of bleeding.2 In this group, candidate 
variants and a genetic diagnosis of platelet-based bleeding was pro-
vided in 40 patients, yielding a detection rate of 72.72% candidate 
variants in this initial cohort using the “manual” filtering method of 
Johnson et al2 (Figure 1A).
More recently, the GAPP study has expanded patients with avail-
able WES data to include 129 individuals with evidence of clinical 
bleeding. Of these, 55 individuals have had a definitive genetic diag-
nosis to identify novel disease-causing genes (eg, SLFN14)3 or new 
pathogenic variants in known genes (eg, GP1BA/B, WAS) yielding an 
overall detection rate of 42.63% (Figure 1B).4,5 Through an extensive 
panel of platelet function testing6 and morphological assessment,7 
these genetic findings have been correlated to the physiological and 
clinical effects of these rare genetic variants. However, the genetic 
causes of bleeding in a significant number of GAPP-recruited patients 
remain unknown, despite an established clinical and family history. 
Here, we assess these individuals through a series of iterative bioin-
formatic filtering approaches to identify novel and “known” candidate 
disease-causing variants.
2  | METHODS
2.1 | Patient recruitment and testing
Patients were consented and recruited to the GAPP study from mul-
tiple collaborating hemophilia centers across the United Kingdom and 
Ireland, as previously described,1 and approved by the UK National 
Research Ethics Service by the Research Ethics Committee of West 
Midlands (06/MRE07/36). Peripheral blood was collected from pa-
tients and platelet phenotyping using lumi-aggregometry or flow 
cytometry was performed on platelet-rich plasma, as previously 
described.6,7
Our study cohort consisted of 129 patients with a strong his-
tory of bleeding and suspected of having a platelet function disor-
der of unknown cause as previously described.1,2 The ISTH Bleeding 
Assessment Tool (BAT) showed a mean score of 9.825 overall (range 
2-23). Platelet counts for the patient group ranged from 43 to 
428 × 109/L and the average platelet count was 232 × 10/L. The 
mean platelet volume in patients tested ranged between 8.3 fL and 
15.1 fL.
2.2 | RNA Sequencing
RNA sequencing (RNAseq) data was provided by KRM and gener-
ated as reported in Machlus et al.8 Briefly, two independent isola-
tions of mouse megakaryocytes (MK; at the round MK, proplatelet, 
and preplatelet/releasate stages) were performed (C57b1/6, 1 
male and 1 female pool, 4-8 mice). Sequencing and analysis were 
performed as described by Rowley et al,9 using the Useq analysis 
package (applying DESeq's negative binomial test).10,11 For analy-
sis, a P value < .05 was used and a false discovery rate of 5%, 
to yield a total of 7094 (3235 up-regulated and 3859 down-reg-
ulated) and 8845 (4125 up-regulated and 4720 down-regulated) 
differentially expressed genes in round versus proplatelet forming 
MKs and proplatelet MK versus preplatelet releasate respectively. 
WES to identify candidate variants forming the basis of future study in a significant 
number of undiagnosed patients.
K E Y W O R D S
bleeding, platelets, megakaryocytes, genetics, RNAseq
Essentials
• Identifying genetic variants in platelet disorders is chal-
lenging due to its heterogenous nature.
• We combine WES, RNAseq, and python-based bioinfor-
matics to identify novel gene variants.
• We find novel candidates in patient data by cross-
referencing against a murine RNAseq model of 
thrombopoiesis.
• This innovative combined bioinformatic approach pro-
vides novel data for future research in the field.
F I G U R E  1   Distribution of known and unknown GAPP patients and the identification of new variants in bleeding genes. (A) In our 
previous report of the GAPP cohort in Johnson et al, a 55 exomes were reported with a total of 40 patients identified as having a clear 
genetic candidate for their inherited platelet-based bleeding. (B) Because the cohort expanded to include 129 exomes, only 55 patients have 
an established genetic cause of bleeding. To date, the cohort with unresolved causes remains at 74 patients. (C) By cross-indexing rare and 
novel variants in GAPP exomes with known bleeding related genes, we identified new candidate genes in a further 59 patients, reducing the 
size of the unknown cohort to 14
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Principal component analysis plots of the samples are included as 
supplementary Figure 3.
2.3 | Analysis approaches
WES analysis was performed in patient genomic DNA, as previ-
ously reported.2 To improve filtering of candidate genetic variants, 
further bioinformatic analysis was performed using python in the 
Pycharm IDE. Exomes were first uploaded as pandas data frames, 
before filtration to identify rare (as in previous work this is classified 
as below a frequency of 0.0001 in exome variant server and the 
1000 genomes) and novel nonsynonymous variants as described 
by Johnson et al. These were cross-referenced against a known list 
of genes that have been previously implicated in inherited causes 
of bleeding. Relevant gene panels used were Inherited Bleeding 
Disorder, high evidence (green), medium evidence (amber), and 
low evidence (red) gene lists, containing 116 genes (supplementary 
Table S1) derived from the Panel app (https://panel app.genom icsen 
gland.co.uk/) and were applied in the project and deemed suitable 
for research purposes. However, of this gene panel, only 88 genes 
from the Genomics England website (R90) are considered suitable 
for clinical use at this time.
The resulting variants were collated and graphed using PRISM 
GraphPad 8. DESeq2 output data was collated as pandas data frames 
depending on the samples analyzed, and visualized using matplotlib 
and seaborn. Unsupervised hierarchical clustering of RNAseq data 
was performed to stratify groups of variants according to their level 
of expression (up-regulated/down-regulated) over the course of 
thrombopoiesis. The annotated scripts are available in GitHub for 
public use (https://github.com/aokha n/gapp-pytho n-proce ssing) 
and further details are available on request.
3  | RESULTS AND DISCUSSION
Of the 129 patients recruited in this study and assessed by the 
GAPP study, 55 have been reported in previous work and are 
now classified as having known causes of bleeding (Figure 1B). 
The unknown cohort comprises 74 patients with extensive clini-
cal bleeding histories, platelet function testing, and WES analysis 
(Figure 1C). Therefore, to identify new candidate gene variants, 
we developed a python-based indexing platform that first filtered 
the 129 patient exomes for rare and novel nonsynonymous and 
indel variants, before cross-referencing the resulting data frame 
with a list of 116 genes already established as clinically causative 
of bleeding (detailed in Methods and supplementary Figure 1). We 
reasoned that an automated approach that uses an up-to-date list 
of clinically relevant platelet-based bleeding genes would better 
identify candidate mutations in the full GAPP cohort. When we 
compared the detection rate using our initial methodology in the 
cohort of 55 exomes/patients reported by Jonson et al to our py-
thon workflow, we identified the original 40 candidate genes, as 
well as an additional 8 candidates through cross-indexing with the 
list of clinical bleeding genes. We observe an increase from 72.3% 
(40 of 55 exomes) to 87.3% (48 of 55).
Expanding this analysis to the full cohort of 129 exomes, rare 
and novel genetic variants in a further 59 individuals, previously part 
of the “unexplained platelet disorder with bleeding” cohort, were 
identified (Figure 1C). These include new and unreported variants in 
established genes (NBEAL2, TUBB1, RUNX1, DIAPH1, VWF),12 as well 
as candidates in lesser-known genes more recently associated with 
bleeding (PTPRJ, MECOM, TPM4).13-15
Our automated indexing of rare and novel variants has ef-
fectively highlighted a number of new candidates in known gene 
categories (which we have labeled “newly identified”), but there 
still remained a cohort of 14 patients with no rare variants in any 
known disease-causing genes. Given that this remaining cohort 
of patients is a challenging one to dissect, we developed a filter-
ing approach based on an expression data resource generated 
from maturing and proplatelet forming murine MKs published by 
Machlus et al.8
RNAseq was performed on populations of murine mature round 
MKs, proplatelet-forming MKs, and released proplatelets to gener-
ate a palette of gene expression data representative of thrombopoi-
esis using an established in vitro model (Figure 2A).8 The data were 
analyzed and processed by DESeq2 and filtered to omit low read 
counts before plotting the resulting 13,062 genes that were signifi-
cantly differentially expressed across the maturation of MKs into 
the process of platelet production (Figure 2B, 2C). These genes were 
plotted as log2 fold change in expression in the round MK versus 
proplatelet-forming MK population (y-axis, Figure 2C) and the pro-
platelet-forming MK versus released proplatelets (x-axis, Figure 2C). 
Therefore, these data represent an array of genes, which are up- and 
down-regulated during and throughout thrombopoiesis.
We next filtered this expression data set against the array of 
known disease-causing genes to validate this approach and found 
that the 116 candidates in this list are evident as a population of 
genes that are differentially expressed in this sample, with base 
mean read sizes visualized by point size and color (Figure 2D). Of 
these, 25 genes were downregulated during thrombopoiesis, 
whereas the remaining 91 were upregulated. An annotated crop of 
this plot in Figure 2D shows established genes well represented by 
the data (GATA1, THPO, TUBB1, MYH9, RUNX1). We then cross-ref-
erenced our rare GAPP-study patient variants with genes repre-
sented in these plots to generate a list of 7034 candidate patient 
variants that were present in this thrombopoiesis data. We then 
performed an unsupervised hierarchical clustering of these genes 
to stratify groups of variants according to their level of expression 
(up-regulated/down-regulated) over the course of thrombopoiesis. 
Finally, we restricted this analysis to our remaining cohort of 14 pa-
tients with unidentified genetic causes of bleeding (supplementary 
Figure 2), and upon filtration and clustering, identified 360 novel 
variants in genes differentially upregulated during thrombopoiesis. 
These genes have not been previously associated with bleeding in 
the literature and therefore represent an opportunity to identify 
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novel players in thrombopoiesis that may be the cause of bleeding in 
this patient cohort.
Among these novel candidates, we found a novel variant in 
DNAI116 in a patient with a documented platelet secretion defect 
(Table 1). Recent work from our group investigating the mecha-
nisms by which the polymodification of TUBB1 mediates platelet 
production reported DNAI1 as a motor protein, which is carefully 
spatially regulated by the posttranslational modification of TUBB1.17 
Mutations in DNAI1 have previously been documented to cause pri-
mary ciliary dyskinesia in a very small number of cases with no evi-
dence of a platelet disorder documented.18 Similarly, in a patient with 
a severe thrombocytopenia (platelet count of 60 × 109/L) and severe 
bleeding (BAT score 13) we found a frameshift insertion in MTMR11 
(encoding human myotubularin 11), a protein that remains unstud-
ied but is abundant in MKs in human bone marrow sections.19 This 
variant has not been reported in a patient or population previously 
(gnomAD accessed August 2020) and with a significant predicted 
pathogenicity score of 37 (combined annotation dependent deple-
tion). In another unrelated individual with a severe macrothrombo-
cytopenia (platelet count of 43 × 109/L, size of 15 fL), a stop/gain 
mutation in an alpha-granule protein, MEGF11,20 was found which 
was again absent in population databases (gnomAD accessed August 
2020) (Table 1, supplementary Figure 2).
In summary, one of the largest challenges in the study of inherited 
bleeding lies in interrogating a significant cohort of patients who, de-
spite extensive study, have yet to yield a conclusive genetic cause of 
disease. This is not only true of the GAPP cohort, but of other stud-
ies focusing on such rare heritable disease.12,21 Therefore, we have 
created an iterative filtration process to highlight new candidate 
variants in a population of patients that, to date, had no identified 
F I G U R E  2   Cross-indexing RNAseq data of maturing and proplatelet producing MKs yields novel candidates in an unknown cohort of 
patients. (A) An RNAseq dataset derived from mature, round MKs, proplatelet-forming MKs, and pre-/platelet releasate was obtained (n = 2). 
(B) A heatmap of differential expression and (C) a plot of fold change across round MK: proplatelet MKs and proplatelet MKs: released 
proplatelets showed that this data set effectively models gene expression during thrombopoiesis. (D) Filtering these data against known 
disease-causing genes and GAPP variants identified up-regulated genes and candidate variants, which include a number of key known genes. 
These data can be further clustered to segment populations of differentially up-regulated and down-regulated genes. (E) Cross-referencing 
rare and novel nonsynonymous variants from the GAPP cohort of 14 unknown patients allowed for the segmentation of candidate novel 
variants which were significantly up-regulated
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cause of bleeding. This approach is open source, automated, and 
easily adaptable to apply filtration to any list of genes of interest.
We use a murine MK model of thrombopoiesis as a model 
RNAseq data set against which we filter our unknown cohort of pa-
tient genomic data. To our knowledge, this is the first such attempt 
to interrogate a clinical cohort of patients with bleeding using a com-
bined WES and RNAseq bioinformatics approach. Although murine 
models of thrombopoiesis are well established and extensively used 
in the study of platelet-based bleeding because of the high degree of 
homology between the species, restricting our analysis to this data 
set is a likely limitation of the study. Future work will focus on ap-
plying this approach in parallel to human models of thrombopoiesis, 
including CD34- and iPSC-derived MKs.
By applying our methods, we generated a large pool of candi-
dates that will become the focus of future studies as we attempt 
to dissect a well-studied but poorly understood cohort of patients. 
Further study is needed to definitively prove the involvement of 
candidate genes and as such, future work will focus on the re-re-
cruitment of patients for mechanistic investigation.
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